
Dr Liu’s project will specifically look at a treatment that combines tPA and sulforaphane (SFN) – a natural compound derived from broccoli. This combination aims to improve the success rate of dissolving blood clots with minimal bleeding risks.
“It is essential that we use a precision-based approach to make the new agent as potent and safe as possible,” Dr Liu added. “Our team has developed specialised screening programs and research models that enable us to carry out this work successfully.”
Dr Liu leads the Cardiovascular-protective Signalling and Drug Discovery Unit at HRI and is also a Conjoint Senior Lecturer and ARC DECRA Fellow at The University of Sydney.
The project will be carried out at both HRI and the School of Chemistry at The University of Sydney.
Funding for this work is generously provided by The Hillcrest Foundation and the Walter and Eileen Ralston Trust.